Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

unknown133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_4

Assessing a Risk Model for G6PD Deficiency

NCT03337152
terminatedphase_2

Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

NCT01290601
unknownphase_3

Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia

NCT02348788

Clinical Trials (3)

Showing 3 of 3 trials
NCT03337152Phase 4

Assessing a Risk Model for G6PD Deficiency

Terminated
NCT01290601Phase 2

Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

Terminated
NCT02348788Phase 3

Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3